Fol­low­ing lethal tox re­port, Boehringer scraps plans for high-speed de­vel­op­ment, kills $730M Han­mi deal

Boehringer-In­gel­heim de­cid­ed to abrupt­ly wash its hands of a $730 mil­lion can­cer drug col­lab­o­ra­tion with Han­mi af­ter a South Ko­re­an min­istry linked the ther­a­py to sev­er­al cas­es of se­vere tox­i­c­i­ty — one of which left a pa­tient dead. Boehringer con­firmed the re­port in a re­ply to End­points News ear­ly Fri­day af­ter­noon, say­ing Ko­re­an of­fi­cials had tracked three cas­es of tox­ic epi­der­mal necrol­y­sis, which can spur he­m­or­rhag­ing and res­pi­ra­to­ry fail­ure.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.